Search This Blog

Wednesday, August 6, 2014

Cholesterol

Cholesterol

From Wikipedia, the free encyclopedia
            
Cholesterol
Cholesterol.svg
Cholesterol-3d.png
Identifiers
CAS number57-88-5 YesY
PubChem5997
ChemSpider5775 YesY
UNII97C5T2UQ7J YesY
KEGGD00040 YesY
ChEBICHEBI:16113 YesY
ChEMBLCHEMBL112570 YesY
Jmol-3D imagesImage 1
Properties
Molecular formulaC27H46O
Molar mass386.65 g/mol
Appearancewhite crystalline powder[2]
Density1.052 g/cm3
Melting point148–150 °C[2]
Boiling point360 °C (decomposes)
Solubility in water0.095 mg/L (30 °C)
Solubilitysoluble in acetone, benzene, chloroform, ethanol, ether, hexane, isopropyl myristate, methanol
Except where noted otherwise, data are given for materials in their standard state (at 25 °C (77 °F), 100 kPa)
 YesY (verify) (what is: YesY/N?)
Infobox references
Microscopic appearance of cholesterol crystals in water. Photo taken under polarized light.

Cholesterol, from the Ancient Greek chole- (bile) and stereos (solid) followed by the chemical suffix -ol for an alcohol, is an organic molecule. It is a sterol (or modified steroid),[3] a lipid molecule and is biosynthesized by all animal cells because it is an essential structural component of animal cell membranes that is required to maintain both membrane structural integrity and fluidity. Cholesterol enables animal cells to (a) not need a cell wall (like plants & bacteria) to protect membrane integrity/cell-viability and thus be able to (b) change shape and (c) move about (unlike bacteria and plant cells which are restricted by their cell walls).

In addition to its importance within cells, cholesterol also serves as a precursor for the biosynthesis of steroid hormones, bile acids, and vitamin D.[4] Cholesterol is the principal sterol synthesized by animals. All kinds of cells in animals can produce it. In vertebrates the hepatic cells typically produce greater amounts than other cells. It is almost completely absent among prokaryotes (bacteria and archaea), although there are some exceptions such as Mycoplasma, which require cholesterol for growth.[5]

François Poulletier de la Salle first identified cholesterol in solid form in gallstones in 1769. However, it was not until 1815 that chemist Michel Eugène Chevreul named the compound "cholesterine".[6][7]

Physiology

Since cholesterol is essential for all animal life, each cell synthesizes it from simpler molecules, a complex 37-step process that starts with the intracellular protein enzyme HMG-CoA reductase. However, normal and particularly high levels of fats (including cholesterol) in the blood circulation, depending on how they are transported within lipoproteins, are strongly associated with the progression of atherosclerosis.

For a man of about 68 kg (150 lb), typical total body-cholesterol synthesis is approximately 1 g (1,000 mg) per day, and total body content is approximately 35 g, primarily located within the membranes of all the cells of the body. Typical daily dietary intake of additional cholesterol, in the United States, is 200–300 mg.[8]

Most ingested cholesterol is esterified, and esterified cholesterol is poorly absorbed. The body also compensates for any absorption of additional cholesterol by reducing cholesterol synthesis.[9] For these reasons, cholesterol intake in food has little, if any, effect on total body cholesterol content or concentrations of cholesterol in the blood.

Cholesterol is recycled. The liver excretes it in a non-esterified form (via bile) into the digestive tract. Typically about 50% of the excreted cholesterol is reabsorbed by the small bowel back into the bloodstream.

Plants make cholesterol in very small amounts.[10] Plants manufacture phytosterols (substances chemically similar to cholesterol produced within plants), which can compete with cholesterol for reabsorption in the intestinal tract, thus potentially reducing cholesterol reabsorption.[11] When intestinal lining cells absorb phytosterols, in place of cholesterol, they usually excrete the phytosterol molecules back into the GI tract, an important protective mechanism.

Function


Cholesterol is required to build and maintain membranes; it modulates membrane fluidity over the range of physiological temperatures. The hydroxyl group on cholesterol interacts with the polar head groups of the membrane phospholipids and sphingolipids, while the bulky steroid and the hydrocarbon chain are embedded in the membrane, alongside the nonpolar fatty-acid chain of the other lipids. Through the interaction with the phospholipid fatty-acid chains, cholesterol increases membrane packing, which reduces membrane fluidity.[12] The structure of the tetracyclic ring of cholesterol contributes to the decreased fluidity of the cell membrane as the molecule is in a trans conformation making all but the side chain of cholesterol rigid and planar.[13] In this structural role, cholesterol reduces the permeability of the plasma membrane to neutral solutes,[14] hydrogen ions, and sodium ions.[15]

Within the cell membrane, cholesterol also functions in intracellular transport, cell signaling and nerve conduction. Cholesterol is essential for the structure and function of invaginated caveolae and clathrin-coated pits, including caveola-dependent and clathrin-dependent endocytosis. The role of cholesterol in such endocytosis can be investigated by using methyl beta cyclodextrin (MβCD) to remove cholesterol from the plasma membrane. Recently, cholesterol has also been implicated in cell signaling processes, assisting in the formation of lipid rafts in the plasma membrane. Lipid raft formation brings receptor proteins in close proximity with high concentrations of second messenger molecules.[16] In many neurons, a myelin sheath, rich in cholesterol, since it is derived from compacted layers of Schwann cell membrane, provides insulation for more efficient conduction of impulses.[17]

Within cells, cholesterol is the precursor molecule in several biochemical pathways. In the liver, cholesterol is converted to bile, which is then stored in the gallbladder. Bile contains bile salts, which solubilize fats in the digestive tract and aid in the intestinal absorption of fat molecules as well as the fat-soluble vitamins, A, D, E, and K. Cholesterol is an important precursor molecule for the synthesis of vitamin D and the steroid hormones, including the adrenal gland hormones cortisol and aldosterone, as well as the sex hormones progesterone, estrogens, and testosterone, and their derivatives.[4]

Some research indicates cholesterol may act as an antioxidant.[18]

Dietary sources

Animal fats are complex mixtures of triglycerides, with lesser amounts of phospholipids and cholesterol. As a consequence, all foods containing animal fat contain cholesterol to varying extents.[19] Major dietary sources of cholesterol include cheese, egg yolks, beef, pork, poultry, fish, and shrimp.[20] Human breast milk also contains significant quantities of cholesterol.[21]

From a dietary perspective, cholesterol is not found in significant amounts in plant sources.[20][22] In addition, plant products such as flax seeds and peanuts contain cholesterol-like compounds called phytosterols, which are believed to compete with cholesterol for absorption in the intestines.[23] Phytosterols can be supplemented through the use of phytosterol-containing functional foods or nutraceuticals that are widely recognized as having a proven LDL cholesterol-lowering efficacy.[24]
Current supplemental guidelines recommend doses of phytosterols in the 1.6-3.0 grams per day range (Health Canada, EFSA, ATP III,FDA) with a recent meta-analysis demonstrating an 8.8% reduction in LDL-cholesterol at a mean dose of 2.15 gram per day.[25] However, the benefits of a diet supplemented with phytosterol has been questioned.[26][27]

Fat intake also plays a role in blood-cholesterol levels. Isocalorically replacing dietary carbohydrates with monounsaturated and polyunsaturated fats has been shown to lower serum LDL and total cholesterol levels and increase serum HDL levels, while replacing carbohydrates with saturated fat was shown to increase HDL, LDL, and total cholesterol levels.[28] Trans fats have been shown to reduce levels of HDL while increasing levels of LDL.[29] Based on such evidence and evidence implicating low HDL and high LDL levels in cardiovascular disease (see Hypercholesterolemia), many health authorities advocate reducing LDL cholesterol through changes in diet in addition to other lifestyle modifications.[30] The USDA, for example, recommends that those wishing to reduce their cholesterol through a change in diet should aim to consume less than 7% of their daily energy needs from saturated fat and fewer than 200 mg of cholesterol per day.[31] An alternative view is that any reduction to dietary cholesterol intake could be counteracted by the organs compensating to try to keep blood cholesterol levels constant.[32] Other research has found that an increase in the consumption of saturated fats and cholesterol decreases overall serum cholesterol.[33]

Biosynthesis

All animal cells manufacture cholesterol for their use, with relative production rates varying by cell type and organ function. About 20–25% of total daily cholesterol production occurs in the liver; other sites of higher synthesis rates include the intestines, adrenal glands, and reproductive organs. Synthesis within the body starts with one molecule of acetyl CoA and one molecule of acetoacetyl-CoA, which are hydrated to form 3-hydroxy-3-methylglutaryl CoA (HMG-CoA).[34] This molecule is then reduced to mevalonate by the enzyme HMG-CoA reductase. This is the regulated, rate-limiting and irreversible step in cholesterol synthesis and is the site of action for the statin drugs (HMG-CoA reductase competitive inhibitors).

Mevalonate is then converted to 3-isopentenyl pyrophosphate in three reactions that require ATP. Mevalonate is decarboxylated to isopentenyl pyrophosphate, which is a key metabolite for various biological reactions. Three molecules of isopentenyl pyrophosphate condense to form farnesyl pyrophosphate through the action of geranyl transferase. Two molecules of farnesyl pyrophosphate then condense to form squalene by the action of squalene synthase in the endoplasmic reticulum.[34] Oxidosqualene cyclase then cyclizes squalene to form lanosterol. Finally, lanosterol is converted to cholesterol through a 19-step process.[35][36]

Konrad Bloch and Feodor Lynen shared the Nobel Prize in Physiology or Medicine in 1964 for their discoveries concerning the mechanism and regulation of cholesterol and fatty acid metabolism.

Regulation of cholesterol synthesis

Biosynthesis of cholesterol is directly regulated by the cholesterol levels present, though the homeostatic mechanisms involved are only partly understood. A higher intake from food leads to a net decrease in endogenous production, whereas lower intake from food has the opposite effect. The main regulatory mechanism is the sensing of intracellular cholesterol in the endoplasmic reticulum by the protein SREBP (sterol regulatory element-binding protein 1 and 2).[37] In the presence of cholesterol, SREBP is bound to two other proteins: SCAP (SREBP cleavage activating protein) and Insig1. When cholesterol levels fall, Insig-1 dissociates from the SREBP-SCAP complex, which allows the complex to migrate to the Golgi apparatus. Here SREBP is cleaved by S1P and S2P (site-1 and -2 protease), two enzymes that are activated by SCAP when cholesterol levels are low.
The cleaved SREBP then migrates to the nucleus, and acts as a transcription factor to bind to the sterol regulatory element (SRE), which stimulates the transcription of many genes. Among these are the low-density lipoprotein (LDL) receptor and HMG-CoA reductase. The LDL receptor former scavenges circulating LDL from the bloodstream, whereas HMG-CoA reductase leads to an increase of endogenous production of cholesterol.[38] A large part of this signaling pathway was clarified by Dr. Michael S. Brown and Dr. Joseph L. Goldstein in the 1970s. In 1985, they received the Nobel Prize in Physiology or Medicine for their work. Their subsequent work shows how the SREBP pathway regulates expression of many genes that control lipid formation and metabolism and body fuel allocation.

Cholesterol synthesis can also be turned off when cholesterol levels are high. HMG-CoA reductase contains both a cytosolic domain (responsible for its catalytic function) and a membrane domain. The membrane domain senses signals for its degradation. Increasing concentrations of cholesterol (and other sterols) cause a change in this domain's oligomerization state, which makes it more susceptible to destruction by the proteosome. This enzyme's activity can also be reduced by phosphorylation by an AMP-activated protein kinase. Because this kinase is activated by AMP, which is produced when ATP is hydrolyzed, it follows that cholesterol synthesis is halted when ATP levels are low.[39]

Plasma transport and regulation of absorption

Cholesterol is only slightly soluble in water; it can dissolve and travel in the water-based bloodstream at exceedingly small concentrations. Since cholesterol is insoluble in blood, it is transported in the circulatory system within lipoproteins, complex discoidal particles that have an exterior composed of amphiphilic proteins and lipids whose outward-facing surfaces are water-soluble and inward-facing surfaces are lipid-soluble; triglycerides and cholesterol esters are carried internally. Phospholipids and cholesterol, being amphipathic, are transported in the surface monolayer of the lipoprotein particle.

In addition to providing a soluble means for transporting cholesterol through the blood, lipoproteins have cell-targeting signals that direct the lipids they carry to certain tissues. For this reason, there are several types of lipoproteins in blood, called, in order of increasing density, chylomicrons, very-low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), low-density lipoprotein (LDL), and high-density lipoprotein (HDL). The more lipid and less protein a lipoprotein has, the less dense it is. The cholesterol within all the various lipoproteins is identical, although some cholesterol is carried as the "free" alcohol and some is carried as fatty acyl esters referred to as cholesterol esters. However, the different lipoproteins contain apolipoproteins, which serve as ligands for specific receptors on cell membranes. In this way, the lipoprotein particles are molecular addresses that determine the start- and endpoints for cholesterol transport.

Chylomicrons, the least dense type of cholesterol transport molecules, contain apolipoprotein B-48, apolipoprotein C, and apolipoprotein E in their shells. Chylomicrons are the transporters that carry fats from the intestine to muscle and other tissues that need fatty acids for energy or fat production. Cholesterol that is not used by muscles remains in more cholesterol-rich chylomicron remnants, which are taken up from here to the bloodstream by the liver.

VLDL molecules are produced by the liver and contain excess triacylglycerol and cholesterol that is not required by the liver for synthesis of bile acids. These molecules contain apolipoprotein B100 and apolipoprotein E in their shells. During transport in the bloodstream, the blood vessels cleave and absorb more triacylglycerol from IDL molecules, which contain an even higher percentage of cholesterol. The IDL molecules have two possible fates: Half are metabolized by HTGL, taken up by the LDL receptor on the liver cell surfaces, and the other half continue to lose triacylglycerols in the bloodstream until they form LDL molecules, which have the highest percentage of cholesterol within them.

LDL molecules, therefore, are the major carriers of cholesterol in the blood, and each one contains approximately 1,500 molecules of cholesterol ester. The shell of the LDL molecule contains just one molecule of apolipoprotein B100, which is recognized by the LDL receptor in peripheral tissues. Upon binding of apolipoprotein B100, many LDL receptors become localized in clathrin-coated pits.
Both the LDL and its receptor are internalized by endocytosis to form a vesicle within the cell. The vesicle then fuses with a lysosome, which has an enzyme called lysosomal acid lipase that hydrolyzes the cholesterol esters. Now within the cell, the cholesterol can be used for membrane biosynthesis or esterified and stored within the cell, so as to not interfere with cell membranes.

Synthesis of the LDL receptor is regulated by SREBP, the same regulatory protein as was used to control synthesis of cholesterol de novo in response to cholesterol presence in the cell. When the cell has abundant cholesterol, LDL receptor synthesis is blocked so new cholesterol in the form of LDL molecules cannot be taken up. On the converse, more LDL receptors are made when the cell is deficient in cholesterol. When this system is deregulated, many LDL molecules appear in the blood without receptors on the peripheral tissues. These LDL molecules are oxidized and taken up by macrophages, which become engorged and form foam cells. These cells often become trapped in the walls of blood vessels and contribute to atherosclerotic plaque formation. Differences in cholesterol homeostasis affect the development of early atherosclerosis (carotid intima-media thickness).[40]
These plaques are the main causes of heart attacks, strokes, and other serious medical problems, leading to the association of so-called LDL cholesterol (actually a lipoprotein) with "bad" cholesterol.[39]

Also, HDL particles are thought to transport cholesterol back to the liver for excretion or to other tissues that use cholesterol to synthesize hormones in a process known as reverse cholesterol transport (RCT).[41] Having large numbers of large HDL particles correlates with better health outcomes.[42] In contrast, having small numbers of large HDL particles is independently associated with atheromatous disease progression in the arteries.

Metabolism, recycling and excretion

Cholesterol is susceptible to oxidation and easily forms oxygenated derivatives known as oxysterols. Three different mechanisms can form these; autoxidation, secondary oxidation to lipid peroxidation, and cholesterol-metabolizing enzyme oxidation. A great interest in oxysterols arose when they were shown to exert inhibitory actions on cholesterol biosynthesis.[43] This finding became known as the “oxysterol hypothesis”. Additional roles for oxysterols in human physiology include their: participation in bile acid biosynthesis, function as transport forms of cholesterol, and regulation of gene transcription.[44]

In biochemical experiments radiolabelled forms of cholesterol, such as tritiated-cholesterol are used. These derivatives undergo degradation upon storage and it is essential to purify cholesterol prior to use. Cholesterol can be purified using small Sephadex LH-20 columns.[45]

Cholesterol is oxidized by the liver into a variety of bile acids.[46] These, in turn, are conjugated with glycine, taurine, glucuronic acid, or sulfate. A mixture of conjugated and nonconjugated bile acids, along with cholesterol itself, is excreted from the liver into the bile. Approximately 95% of the bile acids are reabsorbed from the intestines, and the remainder are lost in the feces.[47] The excretion and reabsorption of bile acids forms the basis of the enterohepatic circulation, which is essential for the digestion and absorption of dietary fats. Under certain circumstances, when more concentrated, as in the gallbladder, cholesterol crystallises and is the major constituent of most gallstones. Although, lecithin and bilirubin gallstones also occur, but less frequently.[48] Every day, up to 1 g of cholesterol enters the colon. This cholesterol originates from the diet, bile, and desquamated intestinal cells, and can be metabolized by the colonic bacteria. Cholesterol is converted mainly into coprostanol, a nonabsorbable sterol that is excreted in the feces. A cholesterol-reducing bacterium origin has been isolated from human feces.[49][non-primary source needed]

Although cholesterol is a steroid generally associated with mammals, the human pathogen Mycobacterium tuberculosis is able to completely degrade this molecule and contains a large number of genes that are regulated by its presence.[50] Many of these cholesterol-regulated genes are homologues of fatty acid β-oxidation genes, but have evolved in such a way as to bind large steroid substrates like cholesterol.[51][52]

Clinical significance

Hypercholesterolemia

According to the lipid hypothesis, abnormal cholesterol levels (hypercholesterolemia) — actually higher concentrations of LDL particles and lower concentrations of functional HDL particles  — are strongly associated with cardiovascular disease because these promote atheroma development in arteries (atherosclerosis). This disease process leads to myocardial infarction (heart attack), stroke, and peripheral vascular disease. Since higher blood LDL, especially higher LDL particle concentrations and smaller LDL particle size, contribute to this process more than the cholesterol content of the HDL particles,[53] LDL particles are often termed "bad cholesterol" because they have been linked to atheroma formation. On the other hand, high concentrations of functional HDL, which can remove cholesterol from cells and atheroma, offer protection and are sometimes referred to as "good cholesterol". These balances are mostly genetically determined, but can be changed by body build, medications, food choices, and other factors.[54] Resistin, a protein secreted by fat tissue, has been shown to increase the production of LDL in human liver cells and also degrades LDL receptors in the liver. As a result, the liver is less able to clear cholesterol from the bloodstream. Resistin accelerates the accumulation of LDL in arteries, increasing the risk of heart disease. Resistin also adversely impacts the effects of statins, the main cholesterol-reducing drug used in the treatment and prevention of cardiovascular disease.[55]

Conditions with elevated concentrations of oxidized LDL particles, especially "small dense LDL" (sdLDL) particles, are associated with atheroma formation in the walls of arteries, a condition known as atherosclerosis, which is the principal cause of coronary heart disease and other forms of cardiovascular disease. In contrast, HDL particles (especially large HDL) have been identified as a mechanism by which cholesterol and inflammatory mediators can be removed from atheroma. Increased concentrations of HDL correlate with lower rates of atheroma progressions and even regression. A 2007 study pooling data on almost 900,000 subjects in 61 cohorts demonstrated that blood total cholesterol levels have an exponential effect on cardiovascular and total mortality, with the association more pronounced in younger subjects. Still, because cardiovascular disease is relatively rare in the younger population, the impact of high cholesterol on health is still larger in older people.[56]

Elevated levels of the lipoprotein fractions, LDL, IDL and VLDL are regarded as atherogenic (prone to cause atherosclerosis).[57] Levels of these fractions, rather than the total cholesterol level, correlate with the extent and progress of atherosclerosis. Conversely, the total cholesterol can be within normal limits, yet be made up primarily of small LDL and small HDL particles, under which conditions atheroma growth rates would still be high. Recently, a post hoc analysis of the IDEAL and the EPIC prospective studies found an association between high levels of HDL cholesterol (adjusted for apolipoprotein A-I and apolipoprotein B) and increased risk of cardiovascular disease, casting doubt on the cardioprotective role of "good cholesterol".[58]

Elevated cholesterol levels are treated with a strict diet consisting of low saturated fat, trans fat-free, low cholesterol foods,[59][60] often followed by one of various hypolipidemic agents, such as statins, fibrates, cholesterol absorption inhibitors, nicotinic acid derivatives or bile acid sequestrants.[61] Extreme cases have previously been treated with partial ileal bypass surgery, which has now been superseded by medication. Apheresis-based treatments are still used for very severe hyperlipidemias that are either unresponsive to treatment or require rapid lowering of blood lipids.[citation needed]
Multiple human trials using HMG-CoA reductase inhibitors, known as statins, have repeatedly confirmed that changing lipoprotein transport patterns from unhealthy to healthier patterns significantly lowers cardiovascular disease event rates, even for people with cholesterol values currently considered low for adults.[62] Studies have also found that statins reduce atheroma progression.[63] As a result, people with a history of cardiovascular disease may derive benefit from statins irrespective of their cholesterol levels (total cholesterol below 5.0 mmol/L [193 mg/dL]),[64] and in men without cardiovascular disease, there is benefit from lowering abnormally high cholesterol levels ("primary prevention").[65] Primary prevention in women was originally practiced only by extension of the findings in studies on men,[66] since, in women, none of the large statin trials conducted prior to 2007 demonstrated a statistically significant reduction in overall mortality or in cardiovascular endpoints.[67] In 2008, a large clinical trial reported that, in apparently healthy adults with increased levels of the inflammatory biomarker high-sensitivity C-reactive protein but with low initial LDL, 20 mg/day of rosuvastatin for 1.9 years resulted in a 44% reduction in the incidence of cardiovascular events and a 20% reduction in all-cause mortality; the effect was statistically significant for both genders.[68] Though this result was met with some skepticism, later studies and meta-analyses likewise demonstrated statistically significant (but smaller) reductions in all-cause and cardiovascular mortality, without significant heterogeneity by gender.[69]

Level mg/dLLevel mmol/LInterpretation
< 200< 5.2Desirable level corresponding to lower risk for heart disease
200–2405.2–6.2Borderline high risk
> 240> 6.2High risk

The 1987 report of National Cholesterol Education Program, Adult Treatment Panels suggests the total blood cholesterol level should be: < 200 mg/dL normal blood cholesterol, 200–239 mg/dL borderline-high, > 240 mg/dL high cholesterol.[70] The American Heart Association provides a similar set of guidelines for total (fasting) blood cholesterol levels and risk for heart disease:[71]

However, as today's testing methods determine LDL ("bad") and HDL ("good") cholesterol separately, this simplistic view has become somewhat outdated. The desirable LDL level is considered to be less than 100 mg/dL (2.6 mmol/L),[72] although a newer upper limit of 70 mg/dL (1.8 mmol/L) can be considered in higher-risk individuals based on some of the above-mentioned trials. A ratio of total cholesterol to HDL—another useful measure—of far less than 5:1 is thought to be healthier.
Reference ranges for blood tests, showing usual, as well as optimal, levels of HDL, LDL and total cholesterol in mass and molar concentrations, is found in orange color at right, that is, among the blood constituents with the highest concentration.

Total cholesterol is defined as the sum of HDL, LDL, and VLDL. Usually, only the total, HDL, and triglycerides are measured. For cost reasons, the VLDL is usually estimated as one-fifth of the triglycerides and the LDL is estimated using the Friedewald formula (or a variant): estimated LDL = [total cholesterol] − [total HDL] − [estimated VLDL]. VLDL can be calculated by dividing total triglycerides by five. Direct LDL measures are used when triglycerides exceed 400 mg/dL. The estimated VLDL and LDL have more error when triglycerides are above 400 mg/dL.[73]

Given the well-recognized role of cholesterol in cardiovascular disease, some studies have shown an inverse correlation between cholesterol levels and mortality. A 2009 study of patients with acute coronary syndromes found an association of hypercholesterolemia with better mortality outcomes.[74] In the Framingham Heart Study, in subjects over 50 years of age, they found an 11% increase overall and 14% increase in cardiovascular disease mortality per 1 mg/dL per year drop in total cholesterol levels. The researchers attributed this phenomenon to the fact that people with severe chronic diseases or cancer tend to have below-normal cholesterol levels.[75] This explanation is not supported by the Vorarlberg Health Monitoring and Promotion Programme, in which men of all ages and women over 50 with very low cholesterol were likely to die of cancer, liver diseases, and mental diseases. This result indicates the low-cholesterol effect occurs even among younger respondents, contradicting the previous assessment among cohorts of older people that this is a proxy or marker for frailty occurring with age.[76]

The vast majority of doctors and medical scientists consider that there is a link between cholesterol and atherosclerosis as discussed above;[77] a small group of scientists, united in The International Network of Cholesterol Skeptics, questions the link.[78] A 2014 meta analysis which followed over 500,000 patients, concluded there is insufficient evidence to support the recommendation of high consumption of polyunsaturated fatty acids and low consumption of total saturated fats for cardiovascular health. [79]

Hypocholesterolemia

Abnormally low levels of cholesterol are termed hypocholesterolemia. Research into the causes of this state is relatively limited, but some studies suggest a link with depression, cancer, and cerebral hemorrhage. In general, the low cholesterol levels seem to be a consequence, rather than a cause, of an underlying illness.[56] A genetic defect in cholesterol synthesis causes Smith-Lemli-Opitz syndrome, which is often associated with low plasma cholesterol levels.

Antimatter

Antimatter

Condensed from Wikipedia, the free encyclopedia
 
Annihilation
In particle physics, antimatter is material composed of antiparticles, which have the same mass as particles of ordinary matter but have opposite charge and other particle properties such as lepton and baryon number. Encounters between particles and antiparticles lead to the annihilation of both, giving rise to varying proportions of high-energy photons (gamma rays), neutrinos, and lower-mass particle–antiparticle pairs. Setting aside the mass of any product neutrinos, which represent released energy which generally continues to be unavailable, the end result of annihilation is a release of energy available to do work, proportional to the total matter and antimatter mass, in accord with the mass-energy equivalence equation, E=mc2.[1]

Antiparticles bind with each other to form antimatter just as ordinary particles bind to form normal matter. For example, a positron (the antiparticle of the electron) and an antiproton can form an antihydrogen atom. Physical principles indicate that complex antimatter atomic nuclei are possible, as well as anti-atoms corresponding to the known chemical elements. To date, however, anti-atoms more complex than antihelium have neither been artificially produced nor observed in nature. Studies of cosmic rays have identified both positrons and antiprotons, presumably produced by high-energy collisions between particles of ordinary matter.

There is considerable speculation as to why the observable universe is apparently composed almost entirely of ordinary matter, as opposed to a more symmetric combination of matter and antimatter. This asymmetry of matter and antimatter in the visible universe is one of the greatest unsolved problems in physics.[2] The process by which this asymmetry between particles and antiparticles developed is called baryogenesis.

Antimatter in the form of anti-atoms is one of the most difficult materials to produce. Antimatter in the form of individual anti-particles, however, is commonly produced by particle accelerators and in some types of radioactive decay.

History of the concept

The idea of negative matter appears in past theories of matter that have now been abandoned. Using the once popular vortex theory of gravity, the possibility of matter with negative gravity was discussed by William Hicks in the 1880s. Between the 1880s and the 1890s, Karl Pearson proposed the existence of "squirts" (sources) and sinks of the flow of aether. The squirts represented normal matter and the sinks represented negative matter. Pearson's theory required a fourth dimension for the aether to flow from and into.[3]

The term antimatter was first used by Arthur Schuster in two rather whimsical letters to Nature in 1898,[4] in which he coined the term. He hypothesized antiatoms, as well as whole antimatter solar systems, and discussed the possibility of matter and antimatter annihilating each other. Schuster's ideas were not a serious theoretical proposal, merely speculation, and like the previous ideas, differed from the modern concept of antimatter in that it possessed negative gravity.[5]

The modern theory of antimatter began in 1928, with a paper[6] by Paul Dirac. Dirac realised that his relativistic version of the Schrödinger wave equation for electrons predicted the possibility of antielectrons. These were discovered by Carl D. Anderson in 1932 and named positrons (a contraction of "positive electrons"). Although Dirac did not himself use the term antimatter, its use follows on naturally enough from antielectrons, antiprotons, etc.[7] A complete periodic table of antimatter was envisaged by Charles Janet in 1929.[8]

Notation

One way to denote an antiparticle is by adding a bar over the particle's symbol. For example, the proton and antiproton are denoted as p and p, respectively. The same rule applies if one were to address a particle by its constituent components. A proton is made up of uud quarks, so an antiproton must therefore be formed from uud antiquarks. Another convention is to distinguish particles by their electric charge. Thus, the electron and positron are denoted simply as e and e+ respectively. However, to prevent confusion, the two conventions are never mixed.

Origin and asymmetry

Almost all matter observable from the Earth seems to be made of matter rather than antimatter. If antimatter-dominated regions of space existed, the gamma rays produced in annihilation reactions along the boundary between matter and antimatter regions would be detectable.[9]

Antiparticles are created everywhere in the universe where high-energy particle collisions take place. High-energy cosmic rays impacting Earth's atmosphere (or any other matter in the Solar System) produce minute quantities of antiparticles in the resulting particle jets, which are immediately annihilated by contact with nearby matter. They may similarly be produced in regions like the center of the Milky Way and other galaxies, where very energetic celestial events occur (principally the interaction of relativistic jets with the interstellar medium). The presence of the resulting antimatter is detectable by the two gamma rays produced every time positrons annihilate with nearby matter. The frequency and wavelength of the gamma rays indicate that each carries 511 keV of energy (i.e., the rest mass of an electron multiplied by c2).

Recent observations by the European Space Agency's INTEGRAL satellite may explain the origin of a giant cloud of antimatter surrounding the galactic center. The observations show that the cloud is asymmetrical and matches the pattern of X-ray binaries (binary star systems containing black holes or neutron stars), mostly on one side of the galactic center. While the mechanism is not fully understood, it is likely to involve the production of electron–positron pairs, as ordinary matter gains tremendous energy while falling into a stellar remnant.[10][11]

Antimatter may exist in relatively large amounts in far-away galaxies due to cosmic inflation in the primordial time of the universe. Antimatter galaxies, if they exist, are expected to have the same chemistry and absorption and emission spectra as normal-matter galaxies, and their astronomical objects would be observationally identical, making them difficult to distinguish.[12] NASA is trying to determine if such galaxies exist by looking for X-ray and gamma-ray signatures of annihilation events in colliding superclusters.[13]

Natural production

Positrons are produced naturally in β+ decays of naturally occurring radioactive isotopes (for example, potassium-40) and in interactions of gamma quanta (emitted by radioactive nuclei) with matter. Antineutrinos are another kind of antiparticle created by natural radioactivity (β decay). Many different kinds of antiparticles are also produced by (and contained in) cosmic rays. Recent (as of January 2011) research by the American Astronomical Society has discovered antimatter (positrons) originating above thunderstorm clouds; positrons are produced in gamma-ray flashes created by electrons accelerated by strong electric fields in the clouds.[14] Antiprotons have also been found to exist in the Van Allen Belts around the Earth by the PAMELA module.[15][16]

Antiparticles are also produced in any environment with a sufficiently high temperature (mean particle energy greater than the pair production threshold). During the period of baryogenesis, when the universe was extremely hot and dense, matter and antimatter were continually produced and annihilated. The presence of remaining matter, and absence of detectable remaining antimatter,[17] also called baryon asymmetry, is attributed to CP-violation: a violation of the CP-symmetry relating matter to antimatter. The exact mechanism of this violation during baryogenesis remains a mystery.

Positrons can be produced by radioactive β+ decay, but this mechanism can occur both naturally and artificially.

Observation in cosmic rays

Satellite experiments have found evidence of positrons and a few antiprotons in primary cosmic rays, amounting to less than 1% of the particles in primary cosmic rays. These do not appear to be the products of large amounts of antimatter from the Big Bang, or indeed complex antimatter in the universe. Rather, they appear to consist of only these two elementary particles, newly made in energetic processes.[citation needed]

Preliminary results from the presently operating Alpha Magnetic Spectrometer (AMS-02) on board the International Space Station show that positrons in the cosmic rays arrive with no directionality, and with energies that range from 10 GeV to 250 GeV, with the fraction of positrons to electrons increasing at higher energies. These results on interpretation have been suggested to be due to positron production in annihilation events of massive dark matter particles.[18]

Antiprotons arrive at Earth with a characteristic energy maximum of 2 GeV, indicating their production in a fundamentally different process from cosmic ray protons, which on average have only one-sixth of the energy.[19]

There is no evidence of complex antimatter atomic nuclei, such as antihelium nuclei (i.e., anti-alpha particles), in cosmic rays. These are actively being searched for. A prototype of the AMS-02 designated AMS-01, was flown into space aboard the Space Shuttle Discovery on STS-91 in June 1998. By not detecting any antihelium at all, the AMS-01 established an upper limit of 1.1×10−6 for the antihelium to helium flux ratio.[20]

Artificial production

Positrons

Positrons were reported[21] in November 2008 to have been generated by Lawrence Livermore National Laboratory in larger numbers than by any previous synthetic process. A laser drove electrons through a millimeter-radius gold target's nuclei, which caused the incoming electrons to emit energy quanta that decayed into both matter and antimatter. Positrons were detected at a higher rate and in greater density than ever previously detected in a laboratory. Previous experiments made smaller quantities of positrons using lasers and paper-thin targets; however, new simulations showed that short, ultra-intense lasers and millimeter-thick gold are a far more effective source.[22]

Antiprotons, antineutrons, and antinuclei

The existence of the antiproton was experimentally confirmed in 1955 by University of California, Berkeley physicists Emilio Segrè and Owen Chamberlain, for which they were awarded the 1959 Nobel Prize in Physics.[23] An antiproton consists of two up antiquarks and one down antiquark (uud). The properties of the antiproton that have been measured all match the corresponding properties of the proton, with the exception of the antiproton having opposite electric charge and magnetic moment from the proton. Shortly afterwards, in 1956, the antineutron was discovered in proton–proton collisions at the Bevatron (Lawrence Berkeley National Laboratory) by Bruce Cork and colleagues.[24]

In addition to antibaryons, anti-nuclei consisting of multiple bound antiprotons and antineutrons have been created. These are typically produced at energies far too high to form antimatter atoms (with bound positrons in place of electrons). In 1965, a group of researchers led by Antonino Zichichi reported production of nuclei of antideuterium at the Proton Synchrotron at CERN.[25] At roughly the same time, observations of antideuterium nuclei were reported by a group of American physicists at the Alternating Gradient Synchrotron at Brookhaven National Laboratory.[26]

Antihydrogen atoms

In 1995, CERN announced that it had successfully brought into existence nine antihydrogen atoms by implementing the SLAC/Fermilab concept during the PS210 experiment. The experiment was performed using the Low Energy Antiproton Ring (LEAR), and was led by Walter Oelert and Mario Macri.[citation needed] Fermilab soon confirmed the CERN findings by producing approximately 100 antihydrogen atoms at their facilities. The antihydrogen atoms created during PS210 and subsequent experiments (at both CERN and Fermilab) were extremely energetic ("hot") and were not well suited to study. To resolve this hurdle, and to gain a better understanding of antihydrogen, two collaborations were formed in the late 1990s, namely, ATHENA and ATRAP. In 2005, ATHENA disbanded and some of the former members (along with others) formed the ALPHA Collaboration, which is also based at CERN. The primary goal of these collaborations is the creation of less energetic ("cold") antihydrogen, better suited to study.[citation needed]

In 1999, CERN activated the Antiproton Decelerator, a device capable of decelerating antiprotons from 3.5 GeV to 5.3 MeV — still too "hot" to produce study-effective antihydrogen, but a huge leap forward. In late 2002 the ATHENA project announced that they had created the world's first "cold" antihydrogen.[27] The ATRAP project released similar results very shortly thereafter.[28] The antiprotons used in these experiments were cooled by decelerating them with the Antiproton Decelerator, passing them through a thin sheet of foil, and finally capturing them in a Penning-Malmberg trap.[29] The overall cooling process is workable, but highly inefficient; approximately 25 million antiprotons leave the Antiproton Decelerator and roughly 25,000 make it to the Penning-Malmberg trap, which is about 11000 or 0.1% of the original amount.

The antiprotons are still hot when initially trapped. To cool them further, they are mixed into an electron plasma. The electrons in this plasma cool via cyclotron radiation, and then sympathetically cool the antiprotons via Coulomb collisions. Eventually, the electrons are removed by the application of short-duration electric fields, leaving the antiprotons with energies less than 100 meV.[30] While the antiprotons are being cooled in the first trap, a small cloud of positrons is captured from radioactive sodium in a Surko-style positron accumulator.[31] This cloud is then recaptured in a second trap near the antiprotons. Manipulations of the trap electrodes then tip the antiprotons into the positron plasma, where some combine with antiprotons to form antihydrogen. This neutral antihydrogen is unaffected by the electric and magnetic fields used to trap the charged positrons and antiprotons, and within a few microseconds the antihydrogen hits the trap walls, where it annihilates. Some hundreds of millions of antihydrogen atoms have been made in this fashion.

Most of the sought-after high-precision tests of the properties of antihydrogen could only be performed if the antihydrogen were trapped, that is, held in place for a relatively long time. While antihydrogen atoms are electrically neutral, the spins of their component particles produce a magnetic moment. These magnetic moments can interact with an inhomogeneous magnetic field; some of the antihydrogen atoms can be attracted to a magnetic minimum. Such a minimum can be created by a combination of mirror and multipole fields.[32] Antihydrogen can be trapped in such a magnetic minimum (minimum-B) trap; in November 2010, the ALPHA collaboration announced that they had so trapped 38 antihydrogen atoms for about a sixth of a second.[33][34] This was the first time that neutral antimatter had been trapped.

On 26 April 2011, ALPHA announced that they had trapped 309 antihydrogen atoms, some for as long as 1,000 seconds (about 17 minutes). This was longer than neutral antimatter had ever been trapped before.[35][36] ALPHA has used these trapped atoms to initiate research into the spectral properties of the antihydrogen.[37]

The biggest limiting factor in the large-scale production of antimatter is the availability of antiprotons. Recent data released by CERN states that, when fully operational, their facilities are capable of producing ten million antiprotons per minute.[38] Assuming a 100% conversion of antiprotons to antihydrogen, it would take 100 billion years to produce 1 gram or 1 mole of antihydrogen (approximately 6.02×1023 atoms of antihydrogen).

Antihelium

Antihelium-3 nuclei (3He) were first observed in the 1970s in proton-nucleus collision experiments[39] and later created in nucleus-nucleus collision experiments.[40] Nucleus-nucleus collisions produce antinuclei through the coalescense of antiprotons and antineutrons created in these reactions. In 2011, the STAR detector reported the observation of Antihelium-4 nuclei (4He).[41]

Uses

Medical

Matter-antimatter reactions have practical applications in medical imaging, such as positron emission tomography (PET). In positive beta decay, a nuclide loses surplus positive charge by emitting a positron (in the same event, a proton becomes a neutron, and a neutrino is also emitted). Nuclides with surplus positive charge are easily made in a cyclotron and are widely generated for medical use. Antiprotons have also been shown within laboratory experiments to have the potential to treat certain cancers, in a similar method currently used for ion (proton) therapy.[47]

Fuel

Isolated and stored anti-matter could be used as a fuel for interplanetary or interstellar travel[48] as part of an antimatter catalyzed nuclear pulse propulsion or other antimatter rocketry, such as the redshift rocket. Since the energy density of antimatter is higher than that of conventional fuels, an antimatter-fueled spacecraft would have a higher thrust-to-weight ratio than a conventional spacecraft.

If matter-antimatter collisions resulted only in photon emission, the entire rest mass of the particles would be converted to kinetic energy. The energy per unit mass (9×1016 J/kg) is about 10 orders of magnitude greater than chemical energies,[49] and about 3 orders of magnitude greater than the nuclear potential energy that can be liberated, today, using nuclear fission (about 200 MeV per fission reaction[50] or 8×1013 J/kg), and about 2 orders of magnitude greater than the best possible results expected from fusion (about 6.3×1014 J/kg for the proton-proton chain). The reaction of kg of antimatter with 1 kg of matter would produce 1.8×1017 J (180 petajoules) of energy (by the mass-energy equivalence formula, E = mc2), or the rough equivalent of 43 megatons of TNT – slightly less than the yield of the 27,000 kg Tsar Bomb, the largest thermonuclear weapon ever detonated.

Not all of that energy can be utilized by any realistic propulsion technology because of the nature of the annihilation products. While electron-positron reactions result in gamma ray photons, these are difficult to direct and use for thrust. In reactions between protons and antiprotons, their energy is converted largely into relativistic neutral and charged pions. The neutral pions decay almost immediately (with a half-life of 84 attoseconds) into high-energy photons, but the charged pions decay more slowly (with a half-life of 26 nanoseconds) and can be deflected magnetically to produce thrust.

Note that charged pions ultimately decay into a combination of neutrinos (carrying about 22% of the energy of the charged pions) and unstable charged muons (carrying about 78% of the charged pion energy), with the muons then decaying into a combination of electrons, positrons and neutrinos (cf. muon decay; the neutrinos from this decay carry about 2/3 of the energy of the muons, meaning that from the original charged pions, the total fraction of their energy converted to neutrinos by one route or another would be about 0.22 + (2/3)*0.78 = 0.74).[51]

Weapons

Antimatter has been considered as a trigger mechanism for nuclear weapons.[52] A major obstacle is the difficulty of producing antimatter in large enough quantities, and there is no evidence that it will ever be feasible.[53] However, the U.S. Air Force funded studies of the physics of antimatter in the Cold War, and began considering its possible use in weapons, not just as a trigger, but as the explosive itself.[54]

Butane

From Wikipedia, the free encyclopedia ...